Mangiferin ameliorates colitis by inhibiting IRAK1 phosphorylation in NF-κB and MAPK pathways. 2014

Jin-Ju Jeong, and Se-Eun Jang, and Supriya R Hyam, and Myung Joo Han, and Dong-Hyun Kim
Department of Life and Nanopharmaceutical Sciences, College of Pharmacy, Kyung Hee University, 1, Hoegi, Dongdaemun-gu, Seoul 130-701, Republic of Korea.

Mangiferin, a main constituent of the root of Anemarrhena asphodeloides and the leaves of Mangifera indica, inhibits NF-κB activation in macrophages. Therefore, we investigated effect of mangiferin on 2,3,4-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice and its anti-inflammatory mechanism in lipolysaccharide (LPS)- or peptidoglycan-stimulated mouse peritoneal macrophages. Mangiferin inhibited phosphorylation of nuclear factor-kappaB (NF-κB), interleukin-1 receptor-associated kinase 1 (IRAK1), and mitogen-activated protein kinases (MAPK) in peptidoglycan- or LPS-stimulated peritoneal macrophages. Mangiferin in the presence of SN50 inhibited LPS-stimulated NF-κB activation more potently than mangiferin alone. Mangiferin inhibited interaction of fluorescent p-IRAK1 antibody to LPS-stimulated peritoneal macrophages, but increased binding of fluorescent IRAK1 antibody. Mangiferin did not influence interaction of fluorescent LPS to toll-like receptor-4 on the macrophages. Molecular peak of mangiferin bound to IRAK1 was detected in the macrophages by mass analysis. Mangiferin (10 μM) inhibited LPS-stimulated expression of TNF-α, IL-1β and IL-6 by 81.0%, 89.5% and 88.3%, respectively, whereas it increased IL-10 expression by 131.8% compared to LPS-nontreated group. Mangiferin furthermore inhibited colon shortening, macroscopic score, and colonic myeloperoxidase activity in TNBS-induced colitic mice. Mangiferin inhibited TNBS-induced IRAK1 phosphorylation and NF-κB activation. Mangiferin suppressed TNBS-induced up-regulation of cyclooxygenase-2 and inducible NO synthase. Furthermore, mangiferin (20mg/kg) significantly inhibited TNF-α by 78%, IL-1β by 82%, and IL-6 expressions by 88% (P<0.05), but induced IL-10 expression to 79% of the normal control group (P<0.05). Based on these findings, mangiferin may ameliorate inflammatory diseases such as colitis by regulating NF-κB and MAPK signaling pathways through the inhibition of IRAK1 phosphorylation.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D010457 Peptidoglycan A structural polymer of the bacterial cell envelope consisting of sugars and amino acids which is responsible for both shape determination and cellular integrity under osmotic stress in virtually all bacteria. Murein,Pseudomurein
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D003092 Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER. Colitides
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D014302 Trinitrobenzenesulfonic Acid A reagent that is used to neutralize peptide terminal amino groups. Picrylsulfonic Acid,Trinitrobenzene Sulfonate,2,4,6-Trinitrobenzene Sulfonate,Trinitrobenzenesulfonic Acid, Sodium Salt,Sulfonate, Trinitrobenzene
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine

Related Publications

Jin-Ju Jeong, and Se-Eun Jang, and Supriya R Hyam, and Myung Joo Han, and Dong-Hyun Kim
September 2015, Respiratory physiology & neurobiology,
Jin-Ju Jeong, and Se-Eun Jang, and Supriya R Hyam, and Myung Joo Han, and Dong-Hyun Kim
April 2011, British journal of pharmacology,
Jin-Ju Jeong, and Se-Eun Jang, and Supriya R Hyam, and Myung Joo Han, and Dong-Hyun Kim
January 2019, Oxidative medicine and cellular longevity,
Jin-Ju Jeong, and Se-Eun Jang, and Supriya R Hyam, and Myung Joo Han, and Dong-Hyun Kim
March 2019, International journal of molecular sciences,
Jin-Ju Jeong, and Se-Eun Jang, and Supriya R Hyam, and Myung Joo Han, and Dong-Hyun Kim
March 2021, Food & function,
Jin-Ju Jeong, and Se-Eun Jang, and Supriya R Hyam, and Myung Joo Han, and Dong-Hyun Kim
March 2024, Alternative therapies in health and medicine,
Jin-Ju Jeong, and Se-Eun Jang, and Supriya R Hyam, and Myung Joo Han, and Dong-Hyun Kim
January 2020, PeerJ,
Jin-Ju Jeong, and Se-Eun Jang, and Supriya R Hyam, and Myung Joo Han, and Dong-Hyun Kim
September 2013, Journal of applied microbiology,
Jin-Ju Jeong, and Se-Eun Jang, and Supriya R Hyam, and Myung Joo Han, and Dong-Hyun Kim
October 2021, International journal of molecular medicine,
Jin-Ju Jeong, and Se-Eun Jang, and Supriya R Hyam, and Myung Joo Han, and Dong-Hyun Kim
August 2017, International immunopharmacology,
Copied contents to your clipboard!